- Conditions
- Episodic Migraine
- Interventions
- Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–41
of 41
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteoarthritis
- Interventions
- Bupivacaine, Morphine, Methylprednisolone, Cefazolin, Normal saline, Midazolam, Propofol, Dexamethasone, 8 MHz. Chiba needle, 22 G / 4 inches
- Drug · Device
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Morton's Neuroma
- Interventions
- Resiniferatoxin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pain Assessment, Quality of Life (QOL), Analgesic Use
- Interventions
- Supplemental Postoperative Bupivacaine, Placebo Injection
- Drug
- Lead sponsor
- New York University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Total Knee Arthroplasty
- Interventions
- Peripheral nerve blocks with Bupivacaine, Intra articular injection with Ropivacaine, Intra articular injection with liposomal bupivacaine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Rotator Cuff Tears, Shoulder Pain
- Interventions
- Liposomal bupivacaine, Bupivacaine Hcl 0.5% Inj, Ropivacaine 0.5% Injectable Solution, Dexamethasone
- Drug
- Lead sponsor
- Hospital for Special Surgery Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- Pain, Postoperative
- Interventions
- Zynrelef (Bupivacaine 60 MG / Meloxicam 1.8 MG) Per 2.3 ML Extended Release Solution, Bupivacaine HCl 0.5% Injectable Solution, primary total knee replacement
- Drug · Procedure
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervical Spine Fusion
- Interventions
- Bupivacaine Hcl 0.25% Inj, Normal saline
- Drug · Other
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Pain, Postoperative, Morbid Obesity
- Interventions
- Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision
- Drug
- Lead sponsor
- Pinnacle Health System
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Harrisburg, Pennsylvania
- Conditions
- Post-operative Pain
- Interventions
- Bupivicaine, placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Pain, Postoperative, Amputation
- Interventions
- Liposomal bupivacaine, Bupivacaine Hydrochloride 0.5 % Injectable Solution
- Drug
- Lead sponsor
- Aurora Quaye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Maine
- Conditions
- Post Operative Pain
- Interventions
- Bupivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, 1.3% liposomal bupivacaine (Exparel), ambIT Infusion Pump
- Drug · Device
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Somerset, New Jersey
- Conditions
- Pain
- Interventions
- Marcaine 0.25 % Injectable Solution
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Postoperative Pain
- Interventions
- lidocaine (1%) + bupivacaine (0.5%), Normal saline, Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pain
- Interventions
- Bipivacaine 0.5% with epinephrine, Normal Saline
- Drug
- Lead sponsor
- Souza, Amanda, M.D.
- Individual
- Eligibility
- 21 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Farmington Hills, Michigan
- Conditions
- Hallux Valgus
- Interventions
- TLC590, Naropin®, Normal Saline, Bupivacaine
- Drug
- Lead sponsor
- Taiwan Liposome Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
- Conditions
- Degenerative Joint Disease
- Interventions
- Group A (corticosteroid injection group), Group B (platelet rich plasma injection group)
- Drug · Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California